|4.26||-0.3200||-6.99%||Vol 24.63K||1Y Perf -56.85%|
|Jul 27th, 2021 13:13 DELAYED|
|-0.21 -4.59%||- -|
|Target Price||17.00||Analyst Rating||Strong Buy 1.00|
|Potential %||285.49||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★ 42.00|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★+ 43.06|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Market Cap||66.00M||Earnings Rating||Neutral|
|Price Range Ratio 52W %||3.64||Earnings Date||24th Mar 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||48.71K|
|Avg. Monthly Volume||40.21K|
|Avg. Quarterly Volume||64.85K|
Celyad Oncology SA (NASDAQ: CYAD) stock closed at 4.58 per share at the end of the most recent trading day (a -1.29% change compared to the prior day closing price) with a volume of 33.30K shares and market capitalization of 66.00M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 107 people. Celyad Oncology SA CEO is Filippo Petti.
The one-year performance of Celyad Oncology SA stock is -56.85%, while year-to-date (YTD) performance is -41.28%. CYAD stock has a five-year performance of -81.23%. Its 52-week range is between 4.01 and 10.87, which gives CYAD stock a 52-week price range ratio of 3.64%
Celyad Oncology SA currently has a PE ratio of -1.90, a price-to-book (PB) ratio of 2.09, a price-to-sale (PS) ratio of 161 555.00, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -34.10%, a ROC of -72.58% and a ROE of -73.04%. The company’s profit margin is -%, its EBITDA margin is -247 654.00%, and its revenue ttm is $445.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Celyad Oncology SA, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Celyad Oncology SA’s next earnings report date is -.
The consensus rating of Wall Street analysts for Celyad Oncology SA is Strong Buy (1), with a target price of $17, which is +285.49% compared to the current price. The earnings rating for Celyad Oncology SA stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Celyad Oncology SA has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Celyad Oncology SA has a Sell technical analysis rating based on Technical Indicators (ADX : 11.20, ATR14 : 0.27, CCI20 : -33.99, Chaikin Money Flow : -0.11, MACD : -0.26, Money Flow Index : 41.66, ROC : -2.76, RSI : 42.87, STOCH (14,3) : 53.77, STOCH RSI : 0.93, UO : 52.39, Williams %R : -46.23), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Celyad Oncology SA in the last 12-months were:
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.